THOR-707 + Pembrolizumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Classic Hodgkin Lymphoma
Conditions
Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
Trial Timeline
Dec 7, 2021 → Sep 6, 2024
NCT ID
NCT05179603About THOR-707 + Pembrolizumab
THOR-707 + Pembrolizumab is a phase 2 stage product being developed by Merck for Classic Hodgkin Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT05179603. Target conditions include Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05179603 | Phase 2 | Terminated |
| NCT04914897 | Phase 2 | Terminated |
Competing Products
15 competing products in Classic Hodgkin Lymphoma